Ascending Multiple Dose Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ILV-094 Administered IV and One Dose of SC Administered to Healthy Subjects.

Trial Profile

Ascending Multiple Dose Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ILV-094 Administered IV and One Dose of SC Administered to Healthy Subjects.

Completed
Phase of Trial: Phase I

Latest Information Update: 14 Jul 2009

At a glance

  • Drugs Fezakinumab (Primary)
  • Indications Psoriasis; Rheumatoid arthritis
  • Focus Adverse reactions; Pharmacokinetics
  • Most Recent Events

    • 14 Jul 2009 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
    • 14 Jul 2009 Actual end date (Feb 2008) added as reported by ClinicalTrials.gov.
    • 14 Jul 2009 Planned patient number (56) added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top